Lisata Therapeutics’ (LSTA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

Lisata Therapeutics Stock Performance

LSTA stock opened at $2.88 on Thursday. The firm has a market cap of $24.18 million, a P/E ratio of -1.15 and a beta of 1.22. The firm’s fifty day moving average is $2.93 and its 200 day moving average is $3.09. Lisata Therapeutics has a 52 week low of $2.05 and a 52 week high of $3.83.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same quarter in the previous year, the business earned ($0.65) EPS. As a group, analysts forecast that Lisata Therapeutics will post -2.84 EPS for the current year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its position in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the Securities & Exchange Commission. 8.94% of the stock is currently owned by institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.